Leronlimab

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1].

Product Specifications

CAS Number

[674782-26-4]

Product Name Alternative

PRO 140

UNSPSC

12352203

Target

CCR; HIV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/leronlimab.html

Purity

98.91

Solubility

10 mM in DMSO

Smiles

[Leronlimab]

Molecular Weight

(146.7 kDa)

References & Citations

[1]Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23 (1) :11.